Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GSK GSK	$38.55 0.0%	$38.86	$31.72 ▼ $44.67	$78.99B	0.52	4.91 million shs	4.92 million shs
TAK Takeda Pharmaceutical	$15.11 +0.3%	$14.83	$12.80 ▼ $15.43	$48.05B	0.23	1.96 million shs	1.54 million shs
VRTX Vertex Pharmaceuticals	$441.30 -0.5%	$454.50	$377.85 ▼ $519.88	$113.32B	0.41	1.42 million shs	3.62 million shs
ZTS Zoetis	$156.17 +0.2%	$160.40	$139.70 ▼ $200.33	$69.53B	0.94	2.56 million shs	2.99 million shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GSK GSK	0.00%	+1.45%	-3.67%	-0.51%	-0.84%
TAK Takeda Pharmaceutical	0.00%	+2.44%	+2.13%	+0.33%	+16.96%
VRTX Vertex Pharmaceuticals	0.00%	+0.10%	-1.30%	-10.43%	-6.90%
ZTS Zoetis	0.00%	-0.69%	-6.57%	-4.21%	-8.64%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GSK GSK	2.0224 of 5 stars	1.1	4.0	2.5	0.0	1.9	0.0	2.5
TAK Takeda Pharmaceutical	0.9355 of 5 stars	0.0	3.0	1.7	0.0	2.5	0.0	0.6
VRTX Vertex Pharmaceuticals	4.6834 of 5 stars	3.3	5.0	0.0	3.3	3.4	2.5	1.3
ZTS Zoetis	4.8096 of 5 stars	3.5	5.0	4.2	0.4	3.0	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GSK GSK	2.10	Hold	$37.38	-3.04% Downside
TAK Takeda Pharmaceutical	3.00	Buy	N/A	N/A
VRTX Vertex Pharmaceuticals	2.54	Moderate Buy	$511.62	15.93% Upside
ZTS Zoetis	3.00	Buy	$212.13	35.83% Upside

Current Analyst Ratings Breakdown

Latest GSK, ZTS, VRTX, and TAK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/23/2025	VRTX Vertex Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$550.00
6/20/2025	VRTX Vertex Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$464.00 ➝ $460.00
6/18/2025	ZTS Zoetis	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$165.00 ➝ $160.00
6/17/2025	VRTX Vertex Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Sector Perform ➝ Sector Perform	$423.00 ➝ $420.00
6/3/2025	GSK GSK	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
5/23/2025	VRTX Vertex Pharmaceuticals	Erste Group Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/12/2025	ZTS Zoetis	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$205.00 ➝ $210.00
5/7/2025	VRTX Vertex Pharmaceuticals	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Peer Perform
5/7/2025	ZTS Zoetis	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$189.00 ➝ $170.00
5/6/2025	VRTX Vertex Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/6/2025	VRTX Vertex Pharmaceuticals	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 6/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GSK GSK	$40.10B	1.97	$5.57 per share	6.92	$8.07 per share	4.78
TAK Takeda Pharmaceutical	$30.09B	1.60	$3.18 per share	4.75	$14.39 per share	1.05
VRTX Vertex Pharmaceuticals	$11.02B	10.28	N/A	N/A	$63.72 per share	6.93
ZTS Zoetis	$9.26B	7.51	$7.07 per share	22.09	$10.57 per share	14.77

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GSK GSK	$3.29B	$1.94	19.87	8.29	1.35	9.89%	48.82%	11.15%	7/30/2025 (Estimated)
TAK Takeda Pharmaceutical	$712.33M	$0.22	68.66	9.15	N/A	2.36%	10.64%	5.14%	7/30/2025 (Estimated)
VRTX Vertex Pharmaceuticals	-$535.60M	-$3.92	N/A	25.20	N/A	-8.91%	-3.36%	-2.42%	7/30/2025 (Estimated)
ZTS Zoetis	$2.49B	$5.57	28.04	23.14	2.59	27.12%	55.48%	19.14%	8/5/2025 (Estimated)

Latest GSK, ZTS, VRTX, and TAK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q4 2025	TAK Takeda Pharmaceutical	$0.24	$0.16	-$0.08	-$0.21	$8.02 billion	$7.34 billion
5/6/2025	Q1 2025	ZTS Zoetis	$1.40	$1.48	+$0.08	$1.41	$2.20 billion	$2.22 billion
5/5/2025	Q1 2025	VRTX Vertex Pharmaceuticals	$4.29	$4.06	-$0.23	$2.49	$2.85 billion	$2.77 billion
4/30/2025	Q1 2025	GSK GSK	$1.08	$1.13	+$0.05	$1.00	$7.52 billion	$10.06 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GSK GSK	$1.69	4.38%	N/A	87.11%	N/A
TAK Takeda Pharmaceutical	$0.27	1.79%	N/A	122.73%	N/A
VRTX Vertex Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ZTS Zoetis	$2.00	1.28%	N/A	35.91%	14 Years

Latest GSK, ZTS, VRTX, and TAK Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/22/2025	ZTS Zoetis	quarterly	$0.50	1.2%	7/18/2025	7/18/2025	9/3/2025
5/2/2025	GSK GSK	quarterly	$0.4216	4.1%	5/16/2025	5/16/2025	7/10/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GSK GSK	1.21	0.87	0.58
TAK Takeda Pharmaceutical	0.57	1.01	0.52
VRTX Vertex Pharmaceuticals	0.01	2.65	2.29
ZTS Zoetis	1.12	1.74	1.04

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GSK GSK	15.74%
TAK Takeda Pharmaceutical	9.17%
VRTX Vertex Pharmaceuticals	90.96%
ZTS Zoetis	92.80%

Insider Ownership

Company	Insider Ownership
GSK GSK	10.00%
TAK Takeda Pharmaceutical	0.04%
VRTX Vertex Pharmaceuticals	0.20%
ZTS Zoetis	0.18%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GSK GSK	68,629	2.05 billion	1.84 billion	Optionable
TAK Takeda Pharmaceutical	49,281	3.18 billion	3.18 billion	Optionable
VRTX Vertex Pharmaceuticals	6,100	256.80 million	256.28 million	Optionable
ZTS Zoetis	13,800	445.21 million	444.41 million	Optionable

GSK, ZTS, VRTX, and TAK Headlines

Recent News About These Companies

Vista Investment Partners II LLC Buys 1,878 Shares of Zoetis Inc. (NYSE:ZTS)

June 28 at 6:39 AM | marketbeat.com

Achmea Investment Management B.V. Increases Stock Position in Zoetis Inc. (NYSE:ZTS)

June 28 at 5:34 AM | marketbeat.com

Sequoia Financial Advisors LLC Sells 170,846 Shares of Zoetis Inc. (NYSE:ZTS)

June 28 at 4:11 AM | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Shares Sold by Bessemer Group Inc.

June 28 at 4:03 AM | marketbeat.com

Should You Invest in Zoetis (ZTS) Based on Bullish Wall Street Views?

June 27 at 10:31 AM | zacks.com

Quilter Plc Has $61.88 Million Stake in Zoetis Inc. (NYSE:ZTS)

June 27 at 8:06 AM | marketbeat.com

Artemis Investment Management LLP Grows Position in Zoetis Inc. (NYSE:ZTS)

June 27 at 7:54 AM | marketbeat.com

Bartlett & CO. Wealth Management LLC Increases Stock Holdings in Zoetis Inc. (NYSE:ZTS)

June 27 at 7:46 AM | marketbeat.com

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Sells 2,410 Shares of Zoetis Inc. (NYSE:ZTS)

June 27 at 7:15 AM | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Shares Purchased by Board of the Pension Protection Fund

June 27 at 6:32 AM | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Shares Sold by Robeco Institutional Asset Management B.V.

June 27 at 5:02 AM | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Shares Sold by Cambridge Investment Research Advisors Inc.

June 27 at 3:46 AM | marketbeat.com

5 Insightful Analyst Questions From Zoetis’s Q1 Earnings Call

June 27 at 2:50 AM | finance.yahoo.com

ZTS - Zoetis Inc Class A Valuation - Morningstar

June 26 at 9:49 PM | morningstar.comM

Zoetis Inc. (NYSE:ZTS) Shares Sold by Penobscot Investment Management Company Inc.

June 26 at 7:02 AM | marketbeat.com

AMI Asset Management Corp Cuts Stake in Zoetis Inc. (NYSE:ZTS)

June 26 at 7:01 AM | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Shares Acquired by Security National Bank

June 26 at 6:14 AM | marketbeat.com

Lecap Asset Management Ltd. Has $1.40 Million Stock Holdings in Zoetis Inc. (NYSE:ZTS)

June 26 at 5:11 AM | marketbeat.com

Stifel Downgrades Zoetis (ZTS) Stock, Reduces PT

June 25, 2025 | insidermonkey.com

ZTS - Zoetis Inc Class A Key Metrics - Morningstar

June 25, 2025 | morningstar.comM

Infosys to offer U.S. animal health firm Zoetis agility, efficiency through digitisation

June 25, 2025 | thehindu.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GSK, ZTS, VRTX, and TAK Company Descriptions

GSK NYSE:GSK

$38.54 -0.01 (-0.01%)

Closing price 06/27/2025 03:59 PM Eastern

Extended Trading

$38.70 +0.15 (+0.39%)

As of 06/27/2025 07:56 PM Eastern

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Takeda Pharmaceutical NYSE:TAK

$15.10 +0.05 (+0.30%)

Closing price 06/27/2025 03:59 PM Eastern

Extended Trading

$15.12 +0.01 (+0.07%)

As of 06/27/2025 07:42 PM Eastern

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

Vertex Pharmaceuticals NASDAQ:VRTX

$441.30 -2.10 (-0.47%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$440.00 -1.30 (-0.29%)

As of 06/27/2025 07:57 PM Eastern

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Zoetis NYSE:ZTS

$156.17 +0.38 (+0.24%)

Closing price 06/27/2025 03:59 PM Eastern

Extended Trading

$156.17 +0.00 (+0.00%)

As of 06/27/2025 05:38 PM Eastern

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time